ClinicalTrialsFinder
RecruitingPhase 4NCT05517655

BEGIN Novel ImagiNG Biomarkers

Sponsor

Children's Hospital Medical Center, Cincinnati

Enrollment

44 participants

Start Date

May 1, 2022

Study Type

INTERVENTIONAL

Conditions

Cystic Fibrosis

Summary

To determine the treatment effect of triple-combination therapy in 6-8 year olds after presumed FDA approval, using rapid structural and functional pulmonary and abdominal MRI (UTE and 129Xe).

Eligibility

Min Age: 6 YearsMax Age: 8 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 129Xe for people with cystic fibrosis. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 6 Years to 8 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG129Xe

Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.

Locations(3)

University of Kansas Medical Center

Kansas City, Kansas, United States

Carrie Stevens

Cincinnati, Ohio, United States

University of Virginia

Charlottesville, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05517655

Related Trials

Role of Genetic Factors in the Development of Lung Disease

NCT000015322 locations

FEED-Cystic Fibrosis (FEED-CF)

NCT057667741 location

Natural History of Noncirrhotic Portal Hypertension

NCT024177401 location

Rare CFTR Mutation Cell Collection Protocol (RARE)

NCT031618081 location

Correction of Nonsense Mutations in Cystic Fibrosis

NCT036704728 locations